Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
L01XX36
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
FDA ORPHAN DRUG |
145501
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
WHO-VATC |
QL01XX36
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
FDA ORPHAN DRUG |
134600
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
GENASENSE (REFUSED: MELANOMA)
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
NCI_THESAURUS |
C1291
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
FDA ORPHAN DRUG |
145601
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
||
|
FDA ORPHAN DRUG |
144901
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
190977-41-4
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108324
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
C408162
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
C1870
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
DB13811
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
85J5ZP6YSL
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
DTXSID60172611
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
8267
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
SUB25230
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
m8098
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
OBLIMERSEN
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
100000089239
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL2109229
Created by
admin on Tue Apr 01 20:35:01 GMT 2025 , Edited by admin on Tue Apr 01 20:35:01 GMT 2025
|
PRIMARY |
| Sugar | Site Range | Site Count |
|---|---|---|
| Deoxyribose (DNA) | 1_1-1_18 | 18 / 18 |
| Linkage | Site Range | Site Count |
|---|---|---|
| Phosporothioate | 1_2-1_18 | 17 / 17 |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)